Paul Tivnan Named Non-Executive Director at Trinity Biotech

Trinity Biotech plc has appointed Paul Tivnan to its Board of Directors as a non-executive director.

Tivnan has more than 25 years of senior leadership experience in finance, capital markets, and corporate governance across the infrastructure, energy, shipping, and cleantech sectors. He currently serves as chief financial officer (CFO) of Deriva Energy LLC, one of the largest independent renewable power producers in the United States and a Brookfield portfolio company. His previous roles include CFO of Brookfield Renewable Ireland and CFO of Ardmore Shipping Corporation, where he led the company’s successful IPO on the New York Stock Exchange in 2013. Tivnan has also served as a director of Element 1 Corp, a developer of advanced hydrogen technologies.

“We are delighted to welcome Paul to the board. His extensive experience in capital markets and operational leadership across large scale global sectors will be invaluable to our company as we continue to execute our transformation strategy and pursue growth opportunities in diagnostics and wearable health technologies,” Trinity Biotech President/CEO John Gillard stated. “Paul’s appointment reflects our commitment to strengthening our corporate governance and bringing diverse, high-impact and international perspectives to the Board, as Trinity Biotech continues to transform and develop.”

Tivnan is a Certified International Director from INSEAD Business School and has completed executive leadership and corporate governance programs at INSEAD and London Business School. Earlier in his career, Tivnan worked at Ernst & Young in Financial Services Advisory, specializing in international tax and corporate structuring.

Tivnan earned a B.A. degree in accounting and finance and a master of business studies degree from Dublin City University. He is a Fellow of the Institute of Chartered Accountants of Ireland, a Chartered Tax Advisor, and a member of the Institute of Chartered Shipbrokers.

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. It has recently entered the wearable biosensor industry with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The firm’s products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells its products directly in the United States and through a network of international distributors and strategic partners in more than 75 countries worldwide.